DOT Oral Fluid Drug Testing: The Regulations Are Ready. Is the Industry?
Senior Business Development Manager
i3screen
With a major regulatory obstacle removed, DOT oral fluid testing is closer to becoming a reality. But laboratory certification is only part of the equation, and widespread availability may take longer than many expect.
In our previous article, we discussed the FDA’s October 6, 2026, decision to remove a longstanding regulatory obstacle that had prevented laboratories from moving forward with federally regulated oral fluid drug testing. Although the Department of Transportation (DOT) authorized oral fluid testing in May 2023, the industry has been waiting more than three years for the laboratory infrastructure needed to make it available.
The FDA decision represents significant progress. Once at least two laboratories are certified by the Department of Health and Human Services (HHS), employers will finally be able to begin using oral fluid testing in their DOT programs.
However, there is a big difference between a testing methodology being permitted by regulation and that methodology being readily available throughout the country. Even after laboratories are certified, several operational, financial, and regulatory considerations could slow adoption.
Electronic Custody and Control Forms Will Take Time
One of the first challenges involves electronic custody and control forms (eCCFs).
Much of the drug testing industry has moved toward electronic ordering and collection workflows, eliminating paperwork, reducing errors, and improving the overall collection experience. For employers, collection sites, laboratories, and service providers accustomed to electronic processes, going back to paper forms may feel like a step backward.
However, federal eCCF approval is a separate process involving the laboratory, the software provider, and the National Laboratory Certification Program (NLCP). Approval involves system review, laboratory submissions, and inspection requirements. These approvals are specific to the laboratory and software provider combination, meaning an existing electronic process cannot simply be assumed to support the new methodology.
Consequently, DOT oral fluid testing may initially be available using paper federal Custody and Control Forms (CCFs) before electronic workflows are approved. For an industry that has invested heavily in integrations and automation, this creates an additional challenge that may influence how quickly oral fluid testing is adopted.
The ability to perform a test and the ability to incorporate that test into an efficient, automated workflow are two very different things.
The Collection Site Economics May Be Different
Another significant challenge, and one that hasn’t received nearly as much attention as laboratory certification, is the economics of oral fluid collection devices.
Today, most laboratories provide urine specimen collection kits to their collection site networks at no charge. The cost of those supplies is generally absorbed into the laboratory’s overall testing economics, allowing collection sites to maintain an inventory without making a significant financial investment.
Oral fluid collection devices present a different situation.
Oral fluid collection kits are considerably more expensive than traditional urine collection supplies, and they have a limited shelf life. That creates an inventory challenge, particularly for collection sites that may only perform a handful of oral fluid collections each month.
Consider a collection site that purchases oral fluid devices in anticipation of demand but only performs a few collections before the remaining devices expire. Unlike the traditional urine collection model, the site may be absorbing the cost of unused inventory.
As a result, we may see laboratories requiring collection sites to purchase oral fluid collection devices rather than providing them at no charge. If that happens, collection sites will need to decide whether the anticipated volume justifies the investment. Some may choose to stock the devices and offer the service immediately, while others may wait until there is sufficient demand. Some may decide not to offer oral fluid collections at all.
This could create a situation where a laboratory is certified to perform DOT oral fluid testing, but an employer’s preferred collection site isn’t equipped to collect the specimen.
Laboratory availability and collection site availability are two very different things. Both will be necessary for oral fluid testing to become a practical alternative to urine testing.
Collector Training and Network Readiness
Having the collection devices available is only part of the challenge. Collection sites also need personnel who are qualified to perform DOT oral fluid collections.
DOT regulations establish specific training and qualification requirements for oral fluid collectors. A collector who is already qualified to perform DOT urine collections isn’t automatically qualified to perform oral fluid collections.
Collection site operators will need to invest in training, qualification demonstrations, procedures, and ongoing competency. For high-volume locations, that investment may be relatively easy to justify. For smaller facilities performing only occasional DOT collections, the economics may be more difficult.
This could also create geographic inconsistencies in availability, particularly during the early stages of implementation. For employers with multiple locations or nationwide testing programs, the question won’t simply be whether oral fluid testing is available. It will be whether the methodology is consistently available across the collection network supporting their workforce.
Understanding the Flexibility Within DOT Regulations
While much of the discussion has focused on when oral fluid testing will become available, employers should also be thinking about how they intend to use it.
One of the most important aspects of the DOT regulations is that employers aren’t required to choose between urine and oral fluid testing. Both methodologies can be incorporated into the same DOT drug testing program, giving employers flexibility to select the appropriate methodology for different circumstances.
For example, an employer may decide to continue using urine testing for routine pre-employment and random testing while using oral fluid testing for certain directly observed collections or other situations where the regulations permit a change in specimen type.
Oral fluid testing may be particularly attractive because collections are directly observed without the same privacy considerations associated with observed urine collections. Oral fluid also generally has a shorter detection window than urine, making it more suited to identifying recent drug use, although neither methodology establishes impairment.
There are important limitations, however. Employers must comply with DOT requirements governing specimen selection, collection procedures, and situations in which a collection methodology can be changed. These decisions cannot be made arbitrarily or in a discriminatory manner.
Standing Orders: An Important Part of the Process
An area that deserves particular attention is the use of standing orders, which are instructions established by the employer to tell the collection site how to proceed under specified circumstances.
Consider an employee who arrives for a DOT urine collection but is unable to provide a sufficient specimen. DOT regulations include procedures under which an oral fluid collection may be used instead, depending on the circumstances and applicable requirements.
Or consider a collection requiring direct observation when an appropriate same-gender observer isn’t available. DOT regulations provide a pathway for using oral fluid testing in that situation, subject to the applicable requirements.
Employers can establish standing orders that communicate their preferences for these situations, rather than requiring the collector to contact the employer’s Designated Employer Representative (DER) every time a decision is needed.
This is where some thoughtful planning can make a meaningful difference.
The value of standing orders isn’t simply regulatory compliance. It’s making sure the collection site knows what to do when something doesn’t go according to plan.
Without clear instructions, collectors may need to stop the process, contact the DER, and wait for direction. That creates delays for the employee, the employer, and the collection site.
Employers should review the permitted uses of oral fluid testing, determine where the methodology makes sense for their programs, and develop standing orders that are consistent with DOT regulations.
They should also remember that standing orders don’t override the regulations. Collectors must follow the specific requirements applicable to the collection being performed, including when switching specimen types is permitted or required.
What Should Employers and Service Providers Be Doing Now?
Although widespread implementation may take time, there is no reason to wait until oral fluid testing becomes available to begin planning.
Employers should be reviewing their DOT drug testing policies, evaluating where oral fluid testing might be beneficial, and considering how their standing orders should address different collection situations. They should also be talking with their service providers about collection site availability, pricing, and how oral fluid testing will be supported.
For CRAs, TPAs, and other drug testing service providers, there is an additional responsibility to prepare for the operational side of implementation. That means understanding which laboratories will offer the service, identifying collection sites that are qualified and equipped to perform oral fluid collections, developing pricing models, and ensuring that ordering systems can support the employer’s instructions.
There is also an opportunity to help clients make better decisions about their programs rather than simply offering another testing option.
Making It Work Is Where the Value Lies
At i3screen, we recognize that the introduction of a new testing methodology involves more than adding another option to an ordering screen.
The laboratory, collection site, technology platform, Medical Review Officer (MRO), and employer’s policies all need to work together. An employer’s standing orders need to be communicated to the collection site, the appropriate methodology needs to be available, and the entire process must remain compliant with DOT regulations.
This is particularly important for CRAs and TPAs managing programs for multiple employers, each of whom may have different requirements and preferences.
Our focus will be on working with our laboratory and collection network partners to help clients navigate these changes and incorporate oral fluid testing into their programs as the necessary infrastructure becomes available.
The Opportunity Is Real, but So Are the Challenges
After more than three years of waiting, the industry has good reason to be optimistic about DOT oral fluid testing. The FDA’s decision removes a significant obstacle, and laboratory certification should provide the next major milestone.
But regulatory authorization doesn’t automatically translate into operational readiness.
Collection site economics, device availability, collector qualifications, electronic workflows, and employer policies will all influence how quickly oral fluid testing becomes a widely available option.
For employers and service providers, the best approach isn’t necessarily to rush into oral fluid testing as soon as it becomes available. It’s to understand where the methodology provides value, prepare for the operational considerations, and develop a thoughtful plan for incorporating it into existing programs.
The door to DOT oral fluid testing is finally opening. The next challenge is making sure the industry is ready to walk through it.
